Characterization of SET/I2PP2A isoforms in dogs

Area of Science:

• Veterinary Oncology
• Molecular Biology
• Biochemistry

Background:

• The SET protein, an endogenous inhibitor of protein phosphatase 2A (PP2A), is linked to poor prognosis in human leukemia.
• Previous research indicated elevated SET protein levels in canine lymphoma cell lines, suggesting potential therapeutic strategies using SET antagonists.

Purpose of the Study:

• To investigate the diversity of SET protein isoforms expressed in canine cells.
• To characterize the genetic location, cellular localization, and PP2A-binding capabilities of these canine SET isoforms.

Main Methods:

• Cloning of four SET isoforms: SETα, SETβ, SETγ, and SETδ.
• Genomic BLAST analysis to determine gene locations on canine chromosomes.
• Immunofluorescence studies to ascertain subcellular localization.
• Confirmation of SETα and SETβ association with PP2A.

Main Results:

• Four distinct SET isoforms (SETα, β, γ, δ) were identified and cloned from canine cells.
• SET genes were mapped to chromosomes X, 7, 1, and 8, respectively.
• SETα and SETβ exhibited nuclear localization, while SETγ and SETδ showed both nuclear and cytosolic distribution.
• SETα and SETβ were confirmed to bind with PP2A.

Conclusions:

• Canine cells express unique SET protein isoforms with varying characteristics.
• These distinct isoforms necessitate consideration in the development of SET-targeting drugs for canine lymphoma.
• Understanding these isoforms is critical for advancing therapeutic strategies in veterinary oncology.